The development of bacterial infection as an adverse effect in telaprevir-based triple therapy for chronic hepatitis C

The development of bacterial infection as an adverse effect in telaprevir-based triple therapy for chronic hepatitis C - Bacterial infection during telaprevir-based triple therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013562

Enrollment

400

Registered

2014-03-30

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C genotype 1

Exclusion criteria

Exclusion criteria: Positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen, clinical or biochemical evidence of hepatic decompensation, hepatocellular carcinoma at entry

Design outcomes

Primary

Measure	Time frame
Bacterial infection	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

Kyushu University Hospital General Internal Medicine

eogawa@gim.med.kyushu-u.ac.jp+81-92-642-5909

Outcome results